BMS-433771 didrochloride drate is a potent orally active inhibitor of respiratory syncytial virus (RSV). BMS-433771 didrochloride drate is active against both A and B groups of RSV, with an average EC50 of 20 nM. BMS-433771 didrochloride drate can be used for the research of respiratory tract disease[1][2].
BMS-433771 didrochloride drate 对 A 组和 B 组 RSV 均具有抑制作用，平均 EC50 为 20 nM[1]。
BMS-433771 didrochloride drate 可抑制病毒 F 蛋白诱导的膜融合[1]。
BMS-433771 didrochloride drate (口服；1-200 mg/kg；每天 1 或 2 次，共 4 天) 通过口服给药显示出预防效果，但两种啮齿动物模型之间具有相当大的药效学差异[2]
.
[1]. Christopher Cianci, et al. Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor. J Antimicrob Chemother
[2]. Christopher Cianci, et al. Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob Agents Chemother. 2004 Jul;48(7):2448-54.